Amelubant

DB06248InvestigationalSmall molecule

Investigated for use/treatment in asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and rheumatoid arthritis.

Mechanism: Amelubant is a long-acting oral Leukotriene B4 (LTB4) receptor antagonist. Amelubant is a prodrug which is metabolized by ubiquitous esterases to BIIL 260 and its glucuronidated metabolite BIIL 315.14. BIIL 260 and BIIL 315.14 interact directly with the LTB4 receptors. LTB4 is a chemotactic factor for immune cells and potentiates the immune response. The G-protein coupled receptors BLT1, (high affinity for LTB4, expressed in most leukocytes) and BLT2 (low affinity for LTB4) are responsible for mediating LTB4's effects.
Curator reviewed
Primary indication: Investigated for use/treatment in asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and rheumatoid arthritis.Curator reviewed
Formula / weight: C₃₃H₃₄N₂O₅ · 538.644 g/mol (avg)
Code names: BIIL-284 · BIIL-284BS · LS-49968

Resolves to

Compound

Structure

InChIKeySBVYURPQULDJTI-UHFFFAOYSA-NSMILESCCOC(=O)NC(=N)C1=CC=C(OCC2=CC=CC(COC3=CC=C(C=C3)C(C)(C)C3=CC=C(O)C=C3)=C2)C=C1

Targets

What you can answer from here — as of August 26, 2024

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amelubant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.